115 related articles for article (PubMed ID: 3051521)
1. Cisplatin pharmacokinetics: applications of a physiological model.
Farris FF; Dedrick RL; King FG
Toxicol Lett; 1988 Oct; 43(1-3):117-37. PubMed ID: 3051521
[TBL] [Abstract][Full Text] [Related]
2. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.
King FG; Dedrick RL; Farris FF
J Pharmacokinet Biopharm; 1986 Apr; 14(2):131-55. PubMed ID: 3746636
[TBL] [Abstract][Full Text] [Related]
3. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.
Farris FF; King FG; Dedrick RL; Litterst CL
J Pharmacokinet Biopharm; 1985 Feb; 13(1):13-39. PubMed ID: 4040567
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
5. [Animal pharmacokinetics in the quantitative estimation of clinical pharmacokinetics of antitumor agents].
Hecquet B
Bull Cancer; 1988; 75(4):385-9. PubMed ID: 3382772
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics.
Zang X; Kagan L
J Pharm Sci; 2024 Jan; 113(1):158-166. PubMed ID: 37866625
[TBL] [Abstract][Full Text] [Related]
8. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
12. Decomposition kinetics of cisplatin in human biological fluids.
Nagai N; Okuda R; Kinoshita M; Ogata H
J Pharm Pharmacol; 1996 Sep; 48(9):918-24. PubMed ID: 8910854
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
14. Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange Study.
Bandu R; Ahn HS; Lee JW; Kim YW; Choi SH; Kim HJ; Kim KP
PLoS One; 2015; 10(8):e0134027. PubMed ID: 26244343
[TBL] [Abstract][Full Text] [Related]
15. Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse.
King FG; Dedrick RL
J Pharmacokinet Biopharm; 1992 Feb; 20(1):95-9. PubMed ID: 1588505
[No Abstract] [Full Text] [Related]
16. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
[TBL] [Abstract][Full Text] [Related]
17. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
18. Platinum tissue concentrations following intra-arterial and intravenous cis-diamminedichloroplatinum II in New Zealand white rabbits.
Carlson JA; Litterst CL; Greenberg RA; Day TG; Masterson BJ
Am J Obstet Gynecol; 1984 Feb; 148(3):313-7. PubMed ID: 6538067
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.
Zakris EL; Dewhirst MW; Riviere JE; Hoopes PJ; Page RL; Oleson JR
J Clin Oncol; 1987 Oct; 5(10):1613-20. PubMed ID: 3655858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
